TherapeuticsMD, Inc.
TXMD · XNASCIK 25743fmd_0NPM3CEFSKFYV4R5D0BDJ25GQGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Jun 30, 2026, 65 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 19 | 17 | 16 | 50 | 65 | 3 | – | 1 | 2 | 3 |
| Cost of revenue | 4 | 3 | 3 | 6 | 16 | 1 | 1 | – | – | – |
| Gross profit | 15 | 14 | 13 | 43 | 49 | 1 | 69 | 1 | – | – |
| Research and development | 54 | 34 | 27 | 20 | 10 | 7 | – | – | – | – |
| Selling, general and administrative | 51 | 58 | 116 | 175 | 194 | 201 | – | 9 | 5 | – |
| Total operating expenses | 105 | 92 | 144 | 195 | 204 | 81 | 67 | 10 | 8 | 7 |
| Operating income | (90) | (78) | (130) | (151) | (156) | (80) | 1 | (9) | (6) | (4) |
| Interest expense | – | – | 5 | 17 | 29 | 33 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | – | – | – | – | – | – | – | 0 | 0 |
| Other non-operating income (expense) | 0 | 1 | (2) | (25) | (28) | 0 | (0) | 1 | 4 | 4 |
| Income before taxes | (90) | (77) | (133) | (176) | (184) | (79) | 1 | (8) | (2) | (1) |
| Income tax expense | – | – | – | – | – | – | – | (0) | (0) | – |
| Net income from continuing operations | – | – | – | – | – | (79) | 1 | (8) | (2) | (1) |
| Net income | (90) | (77) | (133) | (176) | (184) | (172) | 112 | (10) | (2) | (1) |